stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.16
0.26
−4.80%
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) Net income
Regencell Bioscience Holdings Limited's net income for fiscal 2026 was −$11.7M, compared with −$3.6M in fiscal 2025. Over the past ten years it has ranged from −$11.7M (fiscal 2026) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Regencell Bioscience Holdings Limited ranks 48th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2026 | −$11.7M | — |
| FY2025 | −$3.6M | — |
| FY2024 | −$4.4M | — |
| FY2023 | −$6.1M | — |
| FY2022 | −$7.6M | — |
| FY2021 | −$1.3M | — |
| FY2020 | −$812.4K | — |
| FY2019 | −$391.0K | — |
| FY2017 | $0.00 | — |
Against its own ten years
Low −$11.7M
High $0.00
Ten-year median
−$3.6M
Current reading's percentile
11
Net income against peers
| Company | Net income |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $967.7M |
| PBH Prestige Consumer Healthcare Inc. compare | $155.1M |
| XERS Xeris Biopharma Holdings, Inc. compare | −$6.5M |
| RGC Regencell Bioscience Holdings Limited | −$14.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$152.1M |
| ALVO Alvotech compare | −$179.6M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$359.7M |
| TRLV Trulieve Cannabis Corp. compare | −$446.6M |
| PRGO Perrigo Company plc compare | −$1.8B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item